Safety and immunogenicity of the second and third doses of
COVID-19 vaccine in adolescents with rheumatic diseases
Merav Heshin-Bekenstein1,2, Amit
Ziv2,3, Natasa Toplak4,5, Siman
Lazauskas6, Danielle Kadishevich7,
Efrat Ben-Nun Yaari7, Adi
Miller-Barmak8, Yonatan Butbul Aviel8, Esther Saiag9, Sara
Pel10, Ori Elkayam2,10 Yosef
Uziel2,3, Victoria
Furer2,10
1Pediatric Rheumatology Service, Dana-Dwek Children’s
Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
2Sackler Faculty of Medicine, Tel Aviv University, Tel
Aviv, Israel
3Pediatric Rheumatology Unit, Meir Medical Center,
Kfar Saba, Israel
4Department of Allergology, Rheumatology and Clinical
Immunology, University Children’s Hospital, University Medical Center
Ljubljana, Ljubljana, Slovenia
5Faculty of Medicine, University of Ljubljana,
Ljubljana, Slovenia
6Pediatric Department, Dana-Dwek Children’s Hospital,
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
7Pediatric Department, Meir Medical Center, Kfar Saba,
Israel
8Pediatric Rheumatology Unit, Rambam Medical Center,
Haifa, Israel
9Hospital Management, Information and Operation
Branch, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
10Rheumatology Department, Tel Aviv Sourasky Medical
Center, Tel Aviv, Israel
Running title: COVID vaccine in rheumatic adolescents.